Expanding clinical indications in solid tumor oncology, rising adoption of first-line combination regimens, and significant bio-pharmaceutical R&D investments are fueling robust expansion across the global Immune Checkpoint Inhibitor Market. Valued at approximately USD 51.8 billion in 2026, the market is projected to reach USD 122.6 billion by 2036, expanding at a steady compound annual...